TILT Biotherapeutics
Helsinki
About TILT Biotherapeutics
TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. TILT is a preclinical stage company working in the field of cancer immunotherapy and will soon translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR-T therapy of solid tumors as currently achieved for CD19+ hematological tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $71.1M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2025)
- Website: tiltbio.com
Industries & Categories
Apps, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/tilt-biotherapeutics-21161 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.